Vaxart Touts Encouraging Positive Preliminary Data From Bivalent Norovirus Vaccine Study
Portfolio Pulse from Vandana Singh
Vaxart Inc has announced positive preliminary data from the Phase 2 trial of its oral pill bivalent norovirus vaccine candidate. The results showed strong serum immune responses across all doses and a favorable safety profile. The company expects to have additional data in the second half of 2023, which will inform dosage amounts for a Phase 2b study. If successful, this could lead to an End-of-Phase 2 meeting with the FDA in 2024. VXRT shares are currently down 3.11%.
July 06, 2023 | 4:19 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Vaxart's positive preliminary data from the Phase 2 trial of its norovirus vaccine candidate could potentially boost investor confidence in the company's research and development capabilities. However, the company's stock price is currently down.
The positive preliminary data from Vaxart's Phase 2 trial is a significant milestone for the company, indicating progress in its research and development efforts. This could potentially attract more investors, leading to an increase in the company's stock price. However, the current decrease in the company's stock price suggests that the market may have already priced in this news or is reacting to other factors.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100